Related Experiment Video
Updated: Oct 27, 2025
07:12
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
3.8K
SITAgliptin for Depressive Symptoms in Type 2 Diabetes: A Feasibility Randomized Controlled Trial
Calum D Moulton1, Anna S Rokakis, John C Pickup
1From the Departments of Psychological Medicine (Moulton, Young, Rokakis, Ismail) Institute of Psychiatry, Psychology and Neuroscience; Division of Diabetes and Nutritional Sciences (Pickup), Faculty of Life Sciences and Medicine; and Department of Biostatistics (Stahl), Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Psychosomatic Medicine
|July 22, 2021
Summary
This study explored using sitagliptin, a type 2 diabetes medication, for depressive symptoms. While feasible, sitagliptin did not show superiority over placebo in improving depression scores in type 2 diabetes patients.
Area of Science:
- Clinical Medicine
- Pharmacology
- Psychiatry
Background:
- Type 2 diabetes (T2D) often co-occurs with depressive symptoms, impacting patient quality of life.
- Dipeptidyl peptidase-IV inhibitors, like sitagliptin, are used for T2D management.
- The potential role of sitagliptin in addressing depressive symptoms in T2D patients requires investigation.
Purpose of the Study:
- To assess the feasibility of a randomized controlled trial investigating sitagliptin for depressive symptoms in T2D.
- To evaluate the preliminary efficacy of sitagliptin compared to placebo in reducing depressive symptoms in T2D patients.
Main Methods:
- A 12-week, double-blind, randomized controlled trial was conducted.
- Participants with T2D and depressive symptoms were randomized to receive sitagliptin (100 mg/day) or placebo.
- Feasibility outcomes included participation and attrition rates; clinical outcomes assessed depressive symptom scores.
Main Results:
- The trial demonstrated feasibility with acceptable participation and low attrition rates.
- Sitagliptin improved glycemic control (HbA1c) in T2D patients.
- However, sitagliptin did not demonstrate superiority over placebo in reducing depressive symptoms.
Conclusions:
- Repurposing sitagliptin for depressive symptoms in T2D is feasible.
- This feasibility study did not find evidence that sitagliptin is superior to placebo for depression in T2D.
- Larger, longer-term studies are needed to confirm these findings due to the small sample size and short duration.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
363
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
363
01:23Dipeptidyl Peptidase 4 Inhibitors
303
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
303
01:24Glucagon-like Receptor Agonists
498
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
498
01:06Oral Hypoglycemic Agents: Glinides
320
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
320
01:15Diabetes: Management and Pharmacotherapy
597
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
597
01:22Diabetes Mellitus: Type 2 and Gestational
3.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.6K